Corbus Pharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:CRBP)

Analyst Price Target for CRBP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$26.39

▲ +1,416.60% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Corbus Pharmaceuticals in the last 3 months. The average price target is $26.39, with a high forecast of $112.00 and a low forecast of $2.50. The average price target represents a 1,416.60% upside from the last price of $1.74.

Hold

The current consensus among 9 polled investment analysts is to hold stock in Corbus Pharmaceuticals. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/30/2019

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/28/2019

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/26/2020

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/25/2020

0 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/24/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/22/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/21/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

1/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
10/8/2020	HC Wainwright	Lower Price Target	Buy	$6.00 ➝ $3.00	Medium	i
9/9/2020	HC Wainwright	Lower Price Target	Buy	$24.00 ➝ $6.00	High	i
9/8/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High	i Rating by Leland Gershell at Oppenheimer Holdings Inc.
9/8/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$18.00 ➝ $2.50	N/A	i
9/8/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$22.00 ➝ $3.00	N/A	i
9/8/2020	BTIG Research	Downgrade	Buy ➝ Neutral		N/A	i Rating by Dae Gon Ha at BTIG Research
9/8/2020	Roth Capital	Downgrade	Buy ➝ Neutral	$40.00 ➝ $3.00	N/A	i Rating by E. Pierce at Roth Capital
8/7/2020	HC Wainwright	Reiterated Rating	Buy	$24.00	Medium	i
7/27/2020	Jefferies Financial Group	Boost Price Target	Buy	$17.00 ➝ $18.00	High	i
7/7/2020	Roth Capital	Initiated Coverage	Buy	$40.00	High	i Rating by E. Pierce at Roth Capital
6/29/2020	Oppenheimer	Reiterated Rating	Buy	$28.00	High	i Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/19/2020	Oppenheimer	Reiterated Rating	Buy	$28.00	High	i Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/16/2020	BTIG Research	Initiated Coverage	Buy	$22.00	High	i
6/4/2020	Nomura	Boost Price Target	Buy	$12.00 ➝ $32.00	Low	i
6/4/2020	Nomura Instinet	Boost Price Target	Buy	$12.00 ➝ $32.00	Medium	i
5/13/2020	Nomura	Reiterated Rating	Buy	$12.00	Low	i
5/11/2020	Oppenheimer	Reiterated Rating	Buy	$28.00	High	i
3/26/2020	Nomura Securities	Initiated Coverage	Buy	$112.00	High	i
12/23/2019	HC Wainwright	Reiterated Rating	Buy	$24.00	N/A	i Rating by Andrew Fein at HC Wainwright
8/11/2019	Royal Bank of Canada	Reiterated Rating	Buy	$23.00	Medium	i
6/24/2019	HC Wainwright	Set Price Target	Buy	$24.00	Low	i Rating by Andrew Fein at HC Wainwright
5/10/2019	HC Wainwright	Reiterated Rating	Buy	$24.00	High	i Rating by A. Fein at HC Wainwright
4/5/2019	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$18.00 ➝ $18.00	High	i
3/20/2019	CIBC	Initiated Coverage	Outperform ➝ Outperform	$28.00	High	i
3/19/2019	Oppenheimer	Initiated Coverage	Outperform	$28.00 ➝ $28.00	Medium	i
3/12/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$38.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
1/11/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$36.00 ➝ $38.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
1/4/2019	HC Wainwright	Reiterated Rating	Buy	$24.00	Medium	i Rating by A. Fein at HC Wainwright
12/26/2018	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$24.00	Medium	i Rating by A. Fein at HC Wainwright
12/7/2018	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$23.00	High	i
10/24/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$22.00	High	i Rating by G. Zavoico at B. Riley
10/22/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$36.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
10/1/2018	Cantor Fitzgerald	Set Price Target	Buy	$36.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
9/20/2018	Cantor Fitzgerald	Set Price Target	Buy	$36.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
9/13/2018	Cantor Fitzgerald	Set Price Target	Buy	$32.00 ➝ $36.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$32.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
7/25/2018	Cantor Fitzgerald	Set Price Target	Buy	$32.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
5/10/2018	Cantor Fitzgerald	Set Price Target	Buy	$32.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
3/13/2018	Noble Financial	Reiterated Rating	Buy		Medium	i Rating by Caroline Palomeque at Noble Financial
3/12/2018	Cantor Fitzgerald	Set Price Target	Buy	$32.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
1/19/2018	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$24.00	High	i
12/29/2017	Noble Financial	Reiterated Rating	Buy		N/A	i Rating by Caroline Palomeque at Noble Financial
12/23/2017	Noble Financial	Reiterated Rating	Buy		High	i Rating by Caroline Palomeque at Noble Financial
12/15/2017	Noble Financial	Reiterated Rating	Buy		High	i Rating by Caroline Palomeque at Noble Financial
12/14/2017	Cantor Fitzgerald	Set Price Target	Overweight	$24.00 ➝ $28.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
11/8/2017	Noble Financial	Boost Price Target	Buy	$16.00 ➝ $20.00	N/A	i Rating by Kumaraguru Raja at Noble Financial
9/29/2017	Noble Financial	Reiterated Rating	Buy ➝ Buy	$16.00	Medium	i Rating by Kumaraguru Raja at Noble Financial
9/20/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$24.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
8/9/2017	Cantor Fitzgerald	Set Price Target	Buy	$24.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
8/9/2017	Noble Financial	Reiterated Rating	Buy		Low	i Rating by Mark Jordan at Noble Financial
7/17/2017	Cantor Fitzgerald	Set Price Target	Buy	$24.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
6/16/2017	Noble Financial	Reiterated Rating	Buy		High	i Rating by Mark Jordan at Noble Financial
6/13/2017	Cantor Fitzgerald	Set Price Target	Buy	$24.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
5/14/2017	Noble Financial	Reiterated Rating	Buy		Low	i Rating by Mark Jordan at Noble Financial
5/9/2017	Cantor Fitzgerald	Set Price Target	Buy	$24.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
5/6/2017	Noble Financial	Reiterated Rating	Buy		Medium	i Rating by Mark Jordan at Noble Financial
4/7/2017	Noble Financial	Reiterated Rating	Buy		High	i Rating by Mark Jordan at Noble Financial
4/5/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$24.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
4/3/2017	JMP Securities	Reiterated Rating	Outperform	$20.00 ➝ $27.00	Low	i
3/31/2017	Noble Financial	Reiterated Rating	Buy		Low	i Rating by Mark Jordan at Noble Financial
3/30/2017	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$17.00 ➝ $24.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
3/14/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
3/12/2017	Noble Financial	Reiterated Rating	Buy		Medium	i Rating by Mark Jordan at Noble Financial
2/22/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$17.00	N/A	i Rating by Elemer Piros at Cantor Fitzgerald
2/16/2017	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i Rating by Elemer Piros at Cantor Fitzgerald
12/14/2016	Cantor Fitzgerald	Set Price Target	Buy	$17.00	N/A	i
11/30/2016	Aegis	Reiterated Rating	Buy	$12.00	N/A	i Rating by robert leboyer at Aegis
11/15/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	N/A	i
11/15/2016	JMP Securities	Boost Price Target	Outperform	$9.00 ➝ $20.00	N/A	i
11/14/2016	Aegis	Reiterated Rating	Buy		N/A	i Rating by robert leboyer at Aegis
11/11/2016	Noble Financial	Reiterated Rating	Buy	$19.00	N/A	i
10/26/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	N/A	i
10/4/2016	Cantor Fitzgerald	Initiated Coverage	Buy	$17.00	N/A	i
9/19/2016	Aegis	Set Price Target	Buy	$12.00	N/A	i Rating by robert leboyer at Aegis
8/21/2016	Aegis	Reiterated Rating	Buy		N/A	i Rating by R. Leboyer at Aegis
3/31/2016	JMP Securities	Reiterated Rating	Buy		N/A	i Rating by Liisa Bayko at JMP Securities
3/7/2016	Aegis	Initiated Coverage	Buy	$7.00	N/A	i

(Data available from 1/20/2016 forward)

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Today's Range

Now: $1.74

$1.68

$1.76

50 Day Range

MA: $1.43

$1.25

$1.74

52 Week Range

Now: $1.74

$0.91

$9.78

Volume

5,857,033 shs

Average Volume

7,960,552 shs

Market Capitalization

$146.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Corbus Pharmaceuticals?

The following Wall Street analysts have issued research reports on Corbus Pharmaceuticals in the last twelve months: BTIG Research, HC Wainwright, Jefferies Financial Group Inc., Nomura, Nomura Instinet, Nomura Securities, Oppenheimer Holdings Inc., Roth Capital, Royal Bank of Canada, and Zacks Investment Research.

What is the current price target for Corbus Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Corbus Pharmaceuticals in the last year. Their average twelve-month price target is $26.39, suggesting a possible upside of 1,416.6%. Nomura Securities has the highest price target set, predicting CRBP will reach $112.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $2.50 for Corbus Pharmaceuticals in the next year.

What is the current consensus analyst rating for Corbus Pharmaceuticals?

Corbus Pharmaceuticals currently has 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRBP, but not buy more shares or sell existing shares.

What other companies compete with Corbus Pharmaceuticals?

Other companies that are similar to Corbus Pharmaceuticals include Five Prime Therapeutics, Spectrum Pharmaceuticals, Clovis Oncology, Pandion Therapeutics, Atreca, Neoleukin Therapeutics, IDEAYA Biosciences, Dynavax Technologies, Xenon Pharmaceuticals, SIGA Technologies, Prothena, ESSA Pharma, Geron, RAPT Therapeutics and Cogent Biosciences.

How do I contact Corbus Pharmaceuticals' investor relations team?

Corbus Pharmaceuticals' physical mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company's listed phone number is 617-963-0100 and its investor relations email address is ir@corbuspharma.com. The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for CRBP

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Corbus Pharmaceuticals?

What is the current price target for Corbus Pharmaceuticals?

What is the current consensus analyst rating for Corbus Pharmaceuticals?

What other companies compete with Corbus Pharmaceuticals?

How do I contact Corbus Pharmaceuticals' investor relations team?